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Development of an Immunofluorescence Assay Using Recombinant
Proteins Expressed in Insect Cells To Screen and Confirm Presence
of Human Herpesvirus 8-Specific Antibodies䌤
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Pediatrics, Miller School of Medicine, University of Miami, Miami, Florida, 331333
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Human herpesvirus 8 (HHV-8), or Kaposi’s sarcoma (KS)-associated herpesvirus, has been linked to all
forms of KS. The results of most current serological assays for the detection of HHV-8-specific antibodies
have low levels of concordance among themselves. To establish a sensitive and specific testing strategy that
can be used to screen for HHV-8-specific antibodies, three HHV-8 proteins, ORF65, ORF73, and K8.1A,
were expressed by using baculoviral vectors in insect cells and incorporated into a monoclonal antibodyenhanced immunofluorescence assay (mIFA) termed the Sf9 three-antigen mIFA. The results obtained by
this mIFA were compared to those obtained by a standard mIFA with an HHV-8-infected B-cell line (BC3
mIFA). Test sera were obtained from patients diagnosed with KS, human immunodeficiency virus type
1-infected patients at high risk for HHV-8 infection, and healthy controls from a local blood bank. The
combined use of both assays had a sensitivity of 94% and a specificity of 96%. The performance of these
two assays when they were used together indicates that they may be useful for the reliable detection of
HHV-8-specific immunoglobulin G antibodies in a population.
method of choice used in epidemiological studies to screen for
infected individuals.
The development of high-performance serologic tests has
been achieved only to a limited degree due to an incomplete
understanding of the known immunodominant proteins, a lack
of well-characterized uninfected and infected individuals who
may serve as controls, and reported wide variations in antibody
titers among infected individuals. While various serological
assays have been shown to have variable performance characteristics and concordance, immunofluorescence assays (IFAs)
have been considered one of the most sensitive assays for the
detection of antibodies against HHV-8 (11, 23, 27). IFA was
one of the first assays to be used for the detection of HHV-8
antibodies (20). Cell lines derived from patients with PELs and
individuals chronically infected with HHV-8, which mainly express latent and low levels of lytic antigens, have been used for
latent or lytic antgen IFAs. The level of lytic antigens can be
increased by induction with tetradecanoyl phorbol acetate. By
the use of sera from KS patients, several proteins have been
identified to be highly reactive antigens. These include open
reading frame (ORF) proteins 6, 8, 9, 25, 26, 39, 59, 65, 68, and
73; K8.1A; and K8.1B (5). Of these proteins, ORF59, K8.1A,
ORF65, and ORF73 have been used in the development of
various enzyme immunoassays (EIAs) and have been reported
to be good candidate antigens (5, 14, 16, 19, 28, 32). There are
now two commercially available EIAs that use whole-virus
lysate and synthetic peptides.
Here we report on the use of a screening strategy for the
detection of HHV-8-specific antibodies in plasma samples. An
IFA with Sf9 cells expressing predominant proteins encoded by
HHV-8 (ORF65, ORF73, K8.1) was used in conjunction with

Human herpesvirus 8 (HHV-8), also known as Kaposi’s
sarcoma (KS)-associated herpesvirus, is the latest human
herpesvirus to be identified. It has been associated with all
four clinical presentations of KS (the classic, endemic,
AIDS-related, and iatrogenic forms) (6, 15). HHV-8 has
also been detected in patients with primary effusion B-cell
lymphomas (PELs) and multicentric Castleman’s disease
(MCD) (4, 30).
In the general population, the seroprevalence of HHV-8
shows marked geographical variations. HHV-8 infection is endemic in Africa and the Mediterranean region, and in areas
where it is not endemic, it is found at a higher prevalence in
homosexual men and immunosuppressed individuals (8, 9, 13,
24). Its routes of transmission are still not well understood, but
both horizontal transmission and vertical transmission are possible (2, 10, 21). Horizontal transmission can occur by sexual
and nonsexual routes. HHV-8 seroconversion is observed during adulthood among individuals in most developed countries,
most likely due to sexual transmission, and occurs in childhood
in areas of endemicity, most likely due to nonsexual horizontal
transmission. HHV-8 DNA has been detected in saliva, making saliva a potential source of transmission via close interpersonal contact (1–3, 9, 18, 22, 31). HHV-8 DNA cannot be
detected in all infected individuals; therefore, serology is the
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FIG. 2. Scheme used to screen patients for antibodies against
HHV-8 and determine their serological status.

FIG. 1. Western blot analyses of ORF65, ORF73, and K8.1A proteins expressed in Sf9 insect cells. Infected cells were harvested at 72 h
postinfection and were lysed by sonication. Specific proteins were
detected by using anti-GST antibodies. Lanes 1 to 3, ORF65 (48 kDa),
ORF73 (⬎150 kDa), and K8.1A (52 kDa), respectively. Arrows indicate the expressed proteins.

an IFA that uses stimulated BC3 cells to obtain a sensitive and
specific testing strategy.
MATERIALS AND METHODS
Cell culture. BC3 cells (ATCC) were grown in RPMI 1640 medium supplemented with 20% fetal calf serum, L-glutamine, sodium pyruvate, HEPES,
and D-glucose. Sf9 insect cells were maintained as a suspension culture in SF
900 II medium (Invitrogen) supplemented with 10% fetal calf serum and 1%
gentamicin.
Patient sera. A total of 219 samples were used in this study. Of these, 108
samples were collected from patients visiting the Adult Oncology Unit at the
University of Miami Miller School of Medicine. Two plasma samples were
collected from KS patients at the University Teaching Hospital, Lusaka, Zambia,
as a part of an ongoing study that is investigating HHV-8 transmission within
families. Blood banks in Lincoln, NE, and Kansas City, KS, contributed 109
plasma samples. The ethics committee of the Institutional Review Board at the
University of Nebraska approved the study. All samples were coded and
screened without knowledge of the identity of the patient or the diagnosis.
Subsequently, patient serum samples were divided into three groups. Group A
consisted of a total of 33 samples collected from histologically identified KS
patients. This group also included samples from one patient with PEL and one
patient with MCD. Group B (the high-risk group) consisted of 77 samples
collected from human immunodeficiency virus type 1 (HIV-1)-positive patients
with other cancers (not KS, PEL, or MCD). Group C (blood bank donors)
consisted of 109 samples collected from healthy blood bank donors with low-risk
lifestyle behaviors.
Preparation of BC3 cell slides. BC3 cells at a concentration of 7 ⫻ 105 per ml
were treated with tetradecanoyl phorbol acetate at a final concentration of 20
ng/ml for 72 h. The cells were fixed in 4% paraformaldehyde for 20 min at room
temperature, washed with phosphate-buffered saline (PBS), and permeabilized
with 0.1% Triton X-100 for 15 min at room temperature. The cells were washed
and resuspended in PBS. Approximately 10,000 cells were spotted per well onto
12-well Teflon-coated slides (Electron Microscopy Sciences) and stored at
⫺80°C.
Preparation of Sf9 cell slides expressing HHV-8 antigens. Recombinant baculoviruses expressing glutathione S-transferase (GST)-tagged lytic proteins
ORF65 and K8.1A and latent protein ORF73 (provided by Bala Chandran,
Rosalind Franklin University of Medicine and Science, Chicago, IL) were used
to develop the Sf9 cell monoclonal antibody-enhanced IFAs (mIFAs). Baculovirus-infected Sf9 cells expressing GST alone were used as a negative control to

detect background and nonspecific fluorescence. The titers of all baculovirus
stocks were determined, and infections were initiated separately with the three
baculovirus stocks, each of which expressed one recombinant HHV-8 protein at
a multiplicity of infection of 10. Infected cells were monitored daily for viability
and cell diameter by using a Vi-Cell counter (Beckman-Coulter). The expression
of each protein was evaluated by Western blot analysis with anti-GST antibody
(Santa Cruz Biotechnology) following sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (Fig. 1). At 72 h postinfection, the cells were harvested, mixed in
an equal ratio (1:1:1) of viable cells, and subsequently fixed by the BC3 cell
method. This was called the “Sf9 three-antigen” test. All fixed slides were stored
at ⫺80°C.
A modification of the method was also used. At 72 h postinfection, Sf9 cells
infected with baculovirus expressing the ORF73, ORF65, or K8.1 antigen were
harvested, fixed, and spotted individually on separate slides. This method was
used to screen patients for the presence of latent or lytic antibodies and is
referred to as the “single-antigen Sf9 assay.”
mIFAs. All serum samples were diluted 1:40 and centrifuged at high speed for
1 min immediately before they were used. All slides were warmed to room
temperature, individual serum samples were applied to each well, and the slides
were incubated at 37°C for 30 min in a humidified chamber. The slides were
washed (six times) with PBS and were then incubated with mouse anti-human
immunoglobulin G monoclonal antibody at 37°C for 30 min. The slides were
again washed with PBS and then incubated with goat anti-mouse Cy2-conjugated
antibody (Jackson Laboratories) at 37°C for 30 min. After the cells were washed,
they were stained with 0.004% Evans blue for 5 min, washed, and mounted. The
mIFA procedure was the same for BC3 and Sf9 cell slides.
Criteria for being HHV-8 seropositive. All slides were read by two independent readers without knowledge of the patient’s identity, the clinical diagnosis,
the patient’s HIV-1 status, or the other reader’s results. To reduce subjectivity in
observing the specific fluorescence, the slides were read independently by two
experienced laboratory workers. A sample was considered positive if specific
fluorescence was observed by both readers. In the case of discordant results, the
assay was repeated. On repetition, if discordant results were again obtained, then
these patients were considered seronegative. All samples determined to be positive by the BC3 mIFA and the Sf9 three-antigen assay were considered positive.
If a patient was positive by just one assay or negative by both assays, he or she
was considered HHV-8 negative. This testing scheme is summarized in Fig. 2.
Statistical analysis. All data were entered into and analyzed with the SPSS
program (version 15). The kappa statistic was computed to determine the concordance between the standard BC3 mIFA and the Sf9 mIFA. The sensitivity of
detection of HHV-8-specific antibodies was calculated as the number of truepositive samples/(number of true-positive samples ⫹ number of false-negative
samples). All serum samples collected from reliably diagnosed cases of KS, PEL,
and MCD and found to be serologically positive by both assays were considered
true positives. The results were considered false negative if serum samples
collected from these patients were found to be negative by our criteria.
Specificity was calculated as the number of true-negative samples/(number of
true-negative samples ⫹ number of false-positive samples). All serum samples
collected from healthy blood donors and found to be serologically negative by
either assay were considered true negative. The results were considered false
positive if samples collected from these patients were found to be positive.
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RESULTS
HHV-8 seroprevalence. All serum samples were assigned a
unique identification number and were screened blinded by
both mIFAs. Representative mIFA images for a positive and a
negative patient are shown in Fig. 3. After serological screening was completed, the specimens were divided into three
groups on the basis of the patient’s clinical diagnosis, as described in the Materials and Methods section (Table 1). By
using the strategy described in Fig. 2, the overall seroprevalence in group A (KS, PEL, and MCD patients) was 93.9%.
Two samples were considered seronegative, including one
sample which tested positive by the BC3 mIFA but negative by
the Sf9 three-antigen mIFA and a second sample that was not
positive by either of the two assays. The seroprevalence in
group B (the high-risk group) was 58.4%, with 45 of 77 samples
being positive by both assays. The remaining 32 samples were
considered seronegative. Fifteen of these 32 seronegative samples (19.5%) were negative by both assays. Nine (11.7%) and
eight (10.4%) samples were positive by the BC3 mIFA and the
Sf9 three-antigen assay alone, respectively. Both assays detected HHV-8-specific antibodies in only four (3.6%) of the
patients in group C (blood bank donors). The remaining 105
samples were considered seronegative. Of these 105 seronegative samples, 2 (1.8%) and 7 (6.4%) were positive by the BC3
mIFA and the Sf9 three-antigen assay alone, respectively.
Latent and lytic antibody profiles. All samples that were
positive by the Sf9 three-antigen assay were screened by the
single-antigen Sf9 method to ascertain the latent and lytic
antibody profiles present in different groups. Also, we compared the antibody profiles of those samples that were positive
by both the BC3 mIFA and the Sf9 three-antigen assay to those
of samples that were BC3 mIFA negative and Sf9 three-antigen assay positive (Table 2).
BC3 mIFA- and Sf9 three-antigen assay-positive samples.
When the mIFAs were performed with the ORF65, K8.1, and
ORF73 antigens separately, 74% (23/31) of the Sf9 threeantigen mIFA-positive and BC3 mIFA-positive samples in
group A reacted to both the latent (ORF73) and the lytic
(ORF65 or K8.1) antigens. Two samples had detectable antibodies against latent antigen only, and six samples reacted to at
least one lytic antigen. In group B, 64% (29/45) of the seropositive samples reacted to both the latent and the lytic antigens. Eight samples each reacted only to either the latent
antigen or the lytic antigen. In group C, only one of four
seropositive samples was positive for both the latent and the
lytic antigens. Three samples were positive for lytic antigens
only.
BC3 mIFA-negative and Sf9 three-antigen assay-positive
samples. We also wanted to compare the antibody profiles of
patients who were negative by the BC3 mIFA described above.
We did not observe any such sample in group A, but there were
six such samples in group B. All these six samples were negative by the BC3 mIFA and had detectable titers to both the
latent and the lytic antigens, as observed by using the Sf9
three-antigen assay. In the same group, one sample each was
positive for the latent or the lytic antigen only. In group C, we
observed that only one sample was positive for both the latent
and the lytic antigens but that six samples reacted positively to
the lytic antigens.
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Concordance, assay sensitivity, and assay specificity. The
kappa value, which denotes the concordance of the results of
the BC3 mIFA and the Sf9 three-antigen assay, was calculated.
The overall kappa value for all 219 samples was 0.75. The
sensitivity of the screening strategy was then evaluated by using
group A (positive group) samples and was calculated as described in the Materials and Methods section. The sensitivity of
detection of positive samples by this combined strategy was
93.9%. The specificity was calculated by using samples from
group C (blood bank donors). This yielded a specificity of
96.3%.
DISCUSSION
A large proportion of infected but asymptomatic individuals
do not have detectable HHV-8 DNA in their peripheral blood;
therefore, serology is a more reliable method for the identification of HHV-8 infection. However, a major hurdle in obtaining clear data on HHV-8 seroprevalence in a population,
understanding the route of transmission, and routine monitoring of at-risk individuals is the lack of a reliable assay that can
detect antibodies in human sera.
Most laboratories use in-house assays, which have various
levels of sensitivity, specificity, and concordance of results, to
screen for HHV-8-specific antibodies (23, 26, 27). Currently,
no assay is clearly superior because of its sensitivity and specificity. Our goal was to develop a sensitive and specific Sf9
three-antigen IFA that is cost-effective and that can be used as
a confirmatory test to validate IFA results by using HHV-8infected cells. In the study described in this report, both the
BC3 assay and the Sf9 three-antigen assay were used in parallel
to investigate the concordance of results of the two assays.
Given the findings presented in this report, the Sf9 threeantigen assay can be used in tandem as a confirmatory assay
with the BC3 assay for screening for HHV-8-specific antibodies. We used samples from well-characterized patients to evaluate the sensitivity and specificity of this testing strategy. Both
the BC3 and the Sf9 three-antigen mIFAs are designed to
detect HHV-8-specific immunoglobulin G antibodies against
latent and lytic antigens. ORF73 is the major latent protein
and encodes the latency-associated nuclear antigen. ORF65 is
a lytic-phase protein and encodes the minor capsid antigen. It
has been reported to be one of the immunodominant antigens
that can be used for a sensitive serological assay (17). The Sf9
three-antigen assay is flexible because it can be expanded to
incorporate more antigens, if needed. Overexpression of the
immunodominant proteins also helps to easily identify patients
with very low HHV-8-specific antibody titers. Each antigen can
be expressed individually in Sf9 cells to monitor the antibody
responses to latent and lytic antigens separately. More importantly, GST-expressing Sf9 cells served as good negative controls and were used to check for nonspecific binding and fluorescence. This is one of the major drawbacks of using BC3
cells, which lack matched negative control cells. Background or
nonspecific fluorescence, which is commonly found in IFAs,
cannot be ruled out when BC3 or other HHV-8-harboring cell
lines are used. Populations which have been shown to produce
this nonspecific reactivity include serum samples from individuals with high numbers of sexual partners, patients with parasitic infections, and people exposed to a high number of patho-

FIG. 3. Representative staining patterns of mIFAs of ORF65, ORF73, and K8.1A proteins expressed in Sf9 insect cells and BC3 cells by using
positive sera (from patients with KS; left column) and negative sera (from blood bank donors; right column).
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TABLE 1. Seroprevalence of HHV-8-specific antibodies in positive
control group, high-risk group, and blood bank donors

TABLE 2. Antibody profiles of all Sf9 three-antigen-positive
samples against latent (ORF73) and lytic
(ORF65 or K8.1) antigensa

No. (%) of samples
HHV-8 status and assay resulta

HHV-8 positive, BC3⫹/Sf9
three-antigen⫹
HHV-8 negative
BC3⫹/Sf9 three-antigen⫺
BC3⫺/Sf9 three-antigen⫹
BC3⫺/Sf9 three-antigen⫺

Positive
group

High-risk
group

Negative
group

31 (94.0)

45 (58.4)

4 (3.7)

1 (3.0)
0
1 (3.0)

9 (11.7)
8 (10.4)
15 (19.5)

2 (1.8)
7 (6.4)
96 (88.1)

1263

Latent
antigen
profile

⫹
⫹
⫺
Total

Lytic
antigen
profile

⫹
⫺
⫹

No. of samples
Positive group

High-risk group

Negative group

BC3⫹

BC3⫺

BC3⫹

BC3⫺

BC3⫹

BC3⫺

23
2
6

0
0
0

29
8
8

6
1
1

1
0
3

1
0
6

31

0

45

8

4

7

a

A positive sign refers to patients who tested positive by that assay, and a
negative sign refers to patients who tested negative by that assay.

A positive sign refers to patients who tested positive by that assay, and a
negative sign refers to patients who tested negative by that assay.

gens. Residue, sediments, or high lipid contents can also cause
high background fluorescence and was controlled in our assay
by the centrifugation of each sample immediately before it was
used (7).
The criterion that we used to consider a patient HHV-8
positive in our study was based on the results of two IFAs. A
patient was considered positive if the plasma sample gave
specific fluorescence at a dilution of 1:40 by both IFAs. While
this strategy increases the specificity of detection of HHV-8specific antibodies, it may decrease the sensitivity of detection.
By using this testing strategy we could detect HHV-8-specific
antibodies in 94% of clinically diagnosed cases of KS, PEL, and
MCD. Among the positive patients with KS, one patient was
negative by both the BC3 and the Sf9 three-antigen mIFAs.
This patient had undergone antiretroviral treatment after the
development of KS; the treatment could have suppressed the
viral load and led to the complete seroreversion for HHV-8specific antibodies by the time of the present study. Seroreversion has, in fact, been documented in patients after treatment
and the regression of symptoms (25). CD4⫹ cell count data
were not available to help gauge the level of immunosuppression, which may also help explain the unexpected HHV-8 seronegativity. It is possible that the sensitivities of both assays
were too low to detect the very low antibody titer in this
patient. One sample in the positive group was positive by the
BC3 mIFA but negative by the Sf9 mIFA. This could be because nonspecific fluorescence was shown by the BC3 mIFA,
but this cannot be reliably confirmed because of a lack of a
matched negative cell line. It is also likely that for this patient,
none of the three antigens that were expressed in Sf9 cells
elicited an immune response, which further underscores the
importance of using multiple antigens for screening. This suggests that there is a need for the identification and incorporation of more antigens for the routine screening of patients for
HHV-8.
We had chosen the blood bank donor group as our truly
negative controls because blood donors are selected for minimal behavioral risk. Using this testing scheme, we found a
seroprevalence of 3.7% in the blood donor group. This is not
surprising, because a low HHV-8 seroprevalence of about 3%
has been reported in U.S. blood donors (23). We observed a
similar seroprevalence in the blood bank donors, which we had
assumed were negative. In our case, it reduced the specificity
(96%) of this testing strategy. The lack of a “gold standard”

serological assay that can reliably identify patients who are
truly infected versus those who are uninfected makes it difficult
to test the accuracy of the assays currently in use.
Group B patients were included as a test group. The HHV-8
seroprevalence in samples from group B was within the expected range. HIV-1-infected patients from North America
have been reported to have an HHV-8 seroprevalence in the
range of 20 to 50% (12, 20, 29). We observed a similar seroprevalence rate of 58.4% in this group. The antibody profile
showed that 82% of the seropositive samples had lytic antibodies, which is indicative of active replication and which has
been shown to be a risk factor for the development of KS. No
follow-up was available for these patients, and we do not know
if any of them developed KS.
This assay could have some other drawbacks. It is more
labor-intensive than EIA, and reading of the slides can be
subjective. We tried to reduce the subjectivity by employing
two readers who read all the slides independently. EIAs have
frequently employed KS patients to obtain cutoff values for
optical density. This approach might exclude asymptomatic
individuals who are seropositive and frequently have very low
titers of HHV-8-specific antibodies. This method has proven to
be sensitive in detecting HHV-8-specific antibodies from
asymptomatic children and adults in Zambia, a region where
HHV-8 infection is endemic (21a). In our experience, most
asymptomatic individuals in this cohort in Zambia have very
low antibody titers, and the use of EIAs with high cutoff values
is not suitable for such epidemiological studies. We believe
that our stringent criterion for the detection of seropositive
cases may still be underestimating the number of seropositive
cases and reducing the level of sensitivity. However, this
scheme increases the specificity of detection of HHV-8-specific
antibodies by excluding false-positive results. For this study, we
did not test these patient samples for other known ubiquitous
herpesviruses, such as cytomegalovirus, Epstein-Barr virus,
and herpes simplex virus type 1. Our observations for other
adult patient samples from similar locations have shown a very
high seroprevalence.
A reliable serological assay for HHV-8 could be a useful tool
for the accurate monitoring and diagnosis of HHV-8 infection.
In the absence of a gold standard, this strategy has proven to be
helpful in conducting seroepidemiological studies in an area of
endemicity. A greater understanding of the HHV-8 antibody
response is required to perfect the current serological testing

a
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strategy. In conclusion, we describe a new serological approach
that can be used to screen patients for the presence of HHV8-specific antibodies and that is sensitive and specific and reduces the chance of detection of false-positive results. Finally,
further refinement of this approach to incorporate more antigens is ongoing.
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